July 27, 2016 3:04 AM ET


Company Overview of Provista Diagnostics, Inc.

Company Overview

Provista Diagnostics, Inc. develops and commercializes blood-based diagnostic, prognostic, and monitoring tests to address the women's cancers. It designs proteomic tests to detect the presence or absence of cancer and the risk of developing cancer in the future, and perform the tests in its clinical laboratory. The company develops blood-based molecular diagnostic tests to address the breast, ovarian, endometrial, and human papillomavirus (HPV) associated cancers. Its products include Videssa Breast, a biomarker panel along with patient data and statistical modeling to improve standard of care in women with suspicious breast lesions; Videssa Ovarian, a blood-based biomarker assay to aid in ...

55 Broad Street

18th Floor

New York, NY 10004

United States

Founded in 2007





Key Executives for Provista Diagnostics, Inc.

Chief Executive Officer and President
Age: 44
Chief Financial Officer
Chief Operating Officer
Chief Commercial Officer
Clinical Laboratory Director
Compensation as of Fiscal Year 2016.

Provista Diagnostics, Inc. Key Developments

Provista Diagnostics, Inc. Presents at 2016 BIO International Convention, Jun-06-2016 through Jun-09-2016

Provista Diagnostics, Inc. Presents at 2016 BIO International Convention, Jun-06-2016 through Jun-09-2016. Venue: Moscone Center, San Francisco, California, United States. Presentation Date & Speakers: Jun-07-2016. Jun-08-2016, David E. Reese, Chief Executive Officer and President.

Provista Diagnostics Inc. Announces Management Changes

Provista Diagnostics Inc. announced that it has promoted Uriel Kusiatin, to Chief Financial Officer and Kelly Gordon to Vice President of Research and Development. Additionally, the company has filled senior positions on the rapidly expanding commercial team, with Doug Bradley, joining as Vice President of Global Marketing, and Wendy Ross Morray joining as Senior Director of Reimbursement. Mr. Kusiatin began his career at Deloitte and has dedicated the past 25 years to helping companies solve significant business and financial challenges. He has overseen strategy development, operational execution and financial management at numerous companies in the life sciences industry. He has also advised large international pharmaceutical, biotech and medical device companies, as well as start-up companies. Dr. Gordon joined the company in 2015 as Director of Clinical Development. Prior to the company, Gordon served as the CDx Regulatory Affairs Manager for Roche Tissue Diagnostics where she was the contact for a cross-functional team of biostatisticians, clinical affairs managers, data managers, development scientists, manufacturing personnel, marketing managers, pathologists, project managers and quality engineers and managed companion diagnostics projects for oncology drugs at all stages of development. Mr. Bradley joins the company from Caris Life Sciences, where he served as Vice President of Marketing. Prior to Caris, he held the position of Executive Vice President of Global Marketing at Agendia, a molecular diagnostic company that develops and markets genomic assays for early stage breast cancer. He brings extensive experience in marketing in an array of diagnostics, medical devices, and capital equipment for businesses ranging from Fortune 500 market leaders to start-up companies and high-growth enterprises. Ms. Morray joins the company from Prometheus Laboratories Inc., where she served as the Director of Coding and Reimbursement. She has more than 35 years of experience managing coverage and reimbursement strategy, including consulting to laboratories developing and using new technologies. In this capacity, she has advised on reimbursement models given evolving industry and regulatory trends and has helped develop patient assistance programs.

Provista Diagnostics, Inc. Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016

Provista Diagnostics, Inc. Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016. Venue: Hilton Zurich Airport Hotel, 27 Belsize Lane, London | NW3 5AS, United Kingdom. Presentation Date & Speakers: Mar-15-2016, David Reese, President and CEO.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Private Placement
March 8, 2016

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Provista Diagnostics, Inc., please visit www.provistadx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.